Clinical Trials
82 trialsA Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
University of Chicago
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
MK-3475-689
Merck Sharp & Dohme LLC
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
University of Cincinnati
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Merck Sharp & Dohme LLC
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
University of Cincinnati
TACTI-002
Immutep S.A.S.
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
Mayo Clinic
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
PEACH
Royal Marsden NHS Foundation Trust
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
Merck Sharp & Dohme LLC
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
AcceleRET-Lung
Hoffmann-La Roche
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
KEYNOTE-412
Merck Sharp & Dohme LLC
PEMDA-HN
Flamingo Therapeutics NV
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Emory University
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
LEAP-009
Merck Sharp & Dohme LLC
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Wake Forest University Health Sciences
ELEVATE HNSCC
Gilead Sciences
MK-1454-002
Merck Sharp & Dohme LLC
Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Takeda
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Calliditas Therapeutics AB
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
Pembrolizumab in HNSCC With Residual Disease After Radiation
Yale University
MK-3475-048
Merck Sharp & Dohme LLC
MK-3475-B10
Merck Sharp & Dohme LLC
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Viracta Therapeutics, Inc.
Meteor 1
GlaxoSmithKline
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
University of Pittsburgh